Navigation Links
Emory researchers identify signaling protein for multiple myeloma
Date:9/10/2007

Researchers at Emory Universitys Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. Their research may result in identification of a new therapeutic target for treating multiple myeloma.

The results of the study appear in the September issue of Cancer Cell. Jing Chen, PhD, assistant professor of hematology and oncology at Emory Winship and a Georgia Cancer Coalition Distinguished Cancer Scholar, is senior author on the paper. Sumin Kang, PhD, a postdoctoral fellow at Emory Winship, is the paper's first author.

Multiple Myeloma is among the most common hematologic malignancies in patients over 65. About15 percent of multiple myeloma patients harbor a genetic abnormality called t(4;14) chromosomal translocation that causes over-expression of a tyrosine kinase called fibroblast growth factor receptor 3 (FGFR3).

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been identified as a driving force in many forms of cancer.

We are interested in how FGFR3 mediates transforming signals, says Dr. Chen. We wanted to know which protein factors in cells are activated by FGFR3 and then transform normal cells to highly malignant cells. We identified Ribosomal S6 kinase 2 (RSK2), which is a protein factor that mediates signaling in cells as critical in downstream signaling of FGFR3 in myeloma cells.

Dr. Chen and his colleagues are the first to discover a mechanism to turn-on RSK2 by FGFR3. FGFR3 impacts downstream proteins through phosphorylation at special tyrosine sites.

We found that FGFR3 directly phosphorylates RSK2, which is a critical step in the process to activate (turn-on) RSK2, says Dr. Chen.

The researchers observed that elimination of RSK2 proteins or shutting down RSK2 activity blocks FGFR3 transformation signaling in myeloma cells. This means FGFR3 requires RSK2 to transform normal cells.

This is a beautiful model, says Dr. Chen. We are able to mark the connection between the oncogenic FGFR3 and its downstream protein kinase RSK2, which plays a critical role in regulation of cell cycle and survival. These findings extend our understanding of pathogenesis of multiple myeloma in a signaling basis.

Collaborators on the project include Roberto Polakiewicz, PhD, and Ting-Lei Gu, PhD, both of Cell Signaling Technologies (CST), developers of the PhosphoScan technology, which enables investigators to identify hundreds to thousands of phosphorylated sequences and observe the global state of protein tyrosine phosphorylation in cells and tissues.

Using this technology, says Dr. Chen, we identified RSK2 as a critical downstream signaling protein effector of FGFR3 in myeloma cells. Other authors include researchers from the University of California at San Francisco, Harvard Medical School, Mayo Clinic and Novartis Pharma AG.

Dr. Chen and his colleagues also tested a drug called fmk that was designed by co-author Jack Taunton, PhD, at UCSF to specifically target RSK2 in treatment of human malignant myeloma cells from laboratory culture or primary samples from multiple myeloma patients, and saw that fmk effectively kills t(4;14) myeloma cells with abnormal over-expression of FGFR3.

This study shows the potential utility of drugs that block the downstream effectors of mutant tyrosine kinases, and that these drugs are opening more doors to treating hematologic malignancies and cancers," explains Dr. Chen. In addition to the t(4;14) in multiple myeloma that is caused by abnormal over-expression of FGFR3, abnormality of FGFR3 has also been identified in human bladder and cervical cancers. The findings suggest, the authors write, that targeting RSK2 with RSK inhibitors such as fmk may be effective in treating t(4;14) multiple myeloma, as well as other diseases and cancers where mutant FGFR3 is the culprit.


'/>"/>

Contact: Vincent Dollard
vincent.dollard@emoryhealthcare.org
404-778-4580
Emory University
Source:Eurekalert

Related medicine news :

1. Brisk Walking lowers memory loss in women
2. Memory problem? solve a crossword
3. Is there a link between bones and memory?
4. Deep Sleep Doesnt Increase Memory
5. Breakfast improves memory
6. For a Better Memory
7. Left handed have better episodic memory
8. Coffee enhances memory
9. Protein and fat improve memory
10. Memory loss associated with microbes
11. Chew to improve memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... system, has partnered with O2X , an active lifestyle company that provides ... improving the health of firefighters, police offers, first responders, military officers and others ...
(Date:4/21/2017)... Santa Rosa, CA (PRWEB) , ... April 21, ... ... with St. Joseph Health held the much anticipated Regional Primary Care Spring Symposium ... vital role in the local medical community, offering physicians and healthcare providers an ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join the ... festival offers entertainment for everyone — from the avid gardener to the landscape admirer ... high quality event held in a grand venue, and we are certainly looking forward ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in ... bed bug infestations over the 5-year period. In 2015 10% or US$750 million per ... bed bug infested properties. , The health and economic consequences of bed bug ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
(Date:4/18/2017)... , April 18, 2017 Research and ... the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast ... ... molecular imaging equipment revenues as well as growth in the ... will provide value to market participants that design and manufacture ...
(Date:4/18/2017)... TAMPA, Fla. , April 18, 2017 WellCare ... Health Plans, Inc. (NYSE: WCG), announced today it will award ... Kentucky to reduce tobacco use and promote smoke-free ... Center for Smoke-Free Policy conference hosted by the University of ... first time WellCare, the state,s largest Medicaid managed care organization, ...
Breaking Medicine Technology: